Acadia [ACAD] vs BridgeBio Pharma [BBIO] Detailed Stock Comparison
Acadia
NASDAQ
Loading...
BridgeBio Pharma
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Acadia wins in 9 metrics, BridgeBio Pharma wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Acadia | BridgeBio Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 18.64 | -16.98 | BridgeBio Pharma |
| Price-to-Book Ratio | 5.08 | -5.24 | BridgeBio Pharma |
| Debt-to-Equity Ratio | 6.85 | -1.04 | BridgeBio Pharma |
| PEG Ratio | -0.93 | -0.12 | Acadia |
| EV/EBITDA | 33.43 | -17.51 | BridgeBio Pharma |
| Profit Margin (TTM) | 21.80% | 98.25% | BridgeBio Pharma |
| Operating Margin (TTM) | 12.24% | -120.72% | Acadia |
| EBITDA Margin (TTM) | 12.24% | N/A | N/A |
| Return on Equity | 33.18% | 36.76% | BridgeBio Pharma |
| Return on Assets (TTM) | 5.28% | -41.96% | Acadia |
| Free Cash Flow (TTM) | $157.20M | $-529.63M | Acadia |
| 1-Year Return | 61.48% | 93.99% | BridgeBio Pharma |
| Price-to-Sales Ratio (TTM) | 4.10 | 39.80 | Acadia |
| Enterprise Value | $3.48B | $10.92B | BridgeBio Pharma |
| EV/Revenue Ratio | 3.41 | 46.32 | Acadia |
| Gross Profit Margin (TTM) | 92.16% | 96.70% | BridgeBio Pharma |
| Revenue per Share (TTM) | $6 | $1 | Acadia |
| Earnings per Share (Diluted) | $1.33 | $-4.13 | Acadia |
| Beta (Stock Volatility) | 0.71 | 1.23 | Acadia |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Acadia vs BridgeBio Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Acadia | 3.83% | 1.62% | 14.05% | 19.44% | 32.14% | 37.94% |
| BridgeBio Pharma | -2.29% | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Acadia | 61.48% | 55.72% | -32.23% | -32.56% | 2,399.03% | 178.57% |
| BridgeBio Pharma | 93.99% | 368.51% | 65.93% | 82.05% | 82.05% | 82.05% |
Performance & Financial Health Analysis: Acadia vs BridgeBio Pharma
| Metric | ACAD | BBIO |
|---|---|---|
| Market Information | ||
| Market Cap | $4.18B | $9.39B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,926,100 | 3,620,747 |
| 90 Day Avg. Volume | 1,772,320 | 2,736,729 |
| Last Close | $25.74 | $49.08 |
| 52 Week Range | $13.40 - $25.88 | $21.72 - $51.86 |
| % from 52W High | -0.54% | -5.36% |
| All-Time High | $58.72 (Jul 06, 2020) | $73.50 (Feb 08, 2021) |
| % from All-Time High | -56.16% | -33.22% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 50.00% |
| Quarterly Earnings Growth | -0.20% | 50.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.98% |
| Operating Margin (TTM) | 0.12% | -1.21% |
| Return on Equity (TTM) | 0.33% | 0.37% |
| Debt to Equity (MRQ) | 6.85 | -1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.88 | $-9.35 |
| Cash per Share (MRQ) | $4.52 | $3.96 |
| Operating Cash Flow (TTM) | $187.91M | $-655,808,000 |
| Levered Free Cash Flow (TTM) | $53.15M | $-297,633,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Acadia vs BridgeBio Pharma
| Metric | ACAD | BBIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 18.64 | -16.98 |
| Forward P/E | 30.23 | -16.04 |
| PEG Ratio | -0.93 | -0.12 |
| Price to Sales (TTM) | 4.10 | 39.80 |
| Price to Book (MRQ) | 5.08 | -5.24 |
| Market Capitalization | ||
| Market Capitalization | $4.18B | $9.39B |
| Enterprise Value | $3.48B | $10.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.41 | 46.32 |
| Enterprise to EBITDA | 33.43 | -17.51 |
| Risk & Other Metrics | ||
| Beta | 0.71 | 1.23 |
| Book Value per Share (MRQ) | $4.88 | $-9.35 |
Financial Statements Comparison: Acadia vs BridgeBio Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ACAD | BBIO |
|---|---|---|
| Revenue/Sales | $244.32M | $116.63M |
| Cost of Goods Sold | $20.39M | $2.64M |
| Gross Profit | $223.93M | $113.99M |
| Research & Development | $78.27M | $111.43M |
| Operating Income (EBIT) | $19.29M | $-103.80M |
| EBITDA | $22.24M | $-104.46M |
| Pre-Tax Income | $27.78M | $-169.61M |
| Income Tax | $8.79M | N/A |
| Net Income (Profit) | $18.99M | $-169.61M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ACAD | BBIO |
|---|---|---|
| Cash & Equivalents | $217.70M | $540.60M |
| Total Current Assets | $870.94M | $695.17M |
| Total Current Liabilities | $302.53M | $152.11M |
| Long-Term Debt | $44.63M | $1.85B |
| Total Shareholders Equity | $765.24M | $-1.64B |
| Retained Earnings | $-2.19B | $-3.26B |
| Property, Plant & Equipment | $54.11M | $13.86M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ACAD | BBIO |
|---|---|---|
| Operating Cash Flow | $19.58M | $-215.45M |
| Capital Expenditures | N/A | $0 |
| Free Cash Flow | $-78.52M | $-200.83M |
| Debt Repayment | N/A | $-459.00M |
| Common Stock Repurchase | N/A | $-50.05M |
Short Interest & Institutional Ownership Analysis
| Metric | ACAD | BBIO |
|---|---|---|
| Shares Short | 11.03M | 18.52M |
| Short Ratio | 6.36 | 7.46 |
| Short % of Float | 0.10% | 0.16% |
| Average Daily Volume (10 Day) | 1,926,100 | 3,620,747 |
| Average Daily Volume (90 Day) | 1,772,320 | 2,736,729 |
| Shares Outstanding | 166.71M | 190.04M |
| Float Shares | 115.85M | 151.20M |
| % Held by Insiders | 0.01% | 0.05% |
| % Held by Institutions | 1.03% | 1.02% |
Dividend Analysis & Yield Comparison: Acadia vs BridgeBio Pharma
| Metric | ACAD | BBIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |